金乌骨通胶囊治疗膝骨关节炎的Meta分析
该系统评价纳入17项随机对照试验,共1930例膝骨关节炎患者,比较金乌骨通胶囊(单用或联用西药)与常规西药的疗效与安全性;结果显示金乌骨通组在WOMAC、VAS、KSS评分、IL-6、TNF-α及有效率方面均优于西药组,且不良反应发生率更低。
要点
- 金乌骨通胶囊可改善膝骨关节炎的疼痛和功能评分。
- 金乌骨通联合NSAIDs、透明质酸或氨基葡萄糖可提高疗效。
- 金乌骨通组不良反应发生率低于常规西药组。
核心结论
- 金乌骨通胶囊治疗膝骨关节炎有效且安全,值得临床应用。
- 金乌骨通联合NSAIDs、透明质酸或氨基葡萄糖可显著提高后者的临床疗效。
研究设计与样本
- 检索CNKI、万方、SinoMed、PubMed、Embase和Cochrane Library从建库至2021年12月的临床试验。
- 纳入17项随机对照试验,共1930例参与者,试验组1015例,对照组915例。
- 使用Cochrane偏倚风险评估工具评价文献质量,RevMan 5.3软件进行数据分析。
主要发现
- 金乌骨通组WOMAC评分低于西药组(WMD = -6.25,95% CI = -8.09至-4.41,P < 0.001)。
- 金乌骨通组VAS评分低于西药组(WMD = -1.36,95% CI = -2.17至-0.55,P = 0.001)。
- 金乌骨通组KSS评分高于西药组(WMD = 23.01,95% CI = 21.42至24.59,P < 0.001)。
- 金乌骨通组IL-6(SMD = -3.30,95% CI = -4.84至-1.76,P < 0.001)和TNF-α(SMD = -1.70,95% CI = -2.02至-1.38,P < 0.001)低于西药组。
- 金乌骨通组有效率高于西药组(OR = 2.56,95% CI = 1.83至3.57,P < 0.001),不良反应发生率低于西药组(OR = 0.13,95% CI = 0.07至0.21,P < 0.001)。
关键数值与推荐
- 与单用NSAIDs相比,金乌骨通+NSAIDs在有效率(OR = 2.05,95% CI = 1.35至3.12,P < 0.001)和降低不良反应(OR = 0.10,95% CI = 0.06至0.18,P < 0.001)方面更具优势。
- 与单用透明质酸相比,金乌骨通+透明质酸的临床疗效更优(OR = 3.08,95% CI = 1.48至6.40,P < 0.001)。
- 与单用氨基葡萄糖相比,金乌骨通+氨基葡萄糖显著降低Lequesne指数评分(WMD = -0.53,95% CI = -0.85至-0.21,P = 0.001)和血清TNF-α水平(SMD = -1.68,95% CI = -1.93至-1.43,P < 0.001),但在降低血清IL-6水平方面无显著优势(SMD = -4.53,95% CI = -10.13至1.07,P = 0.11)。
临床怎么用
- 膝骨关节炎患者可考虑使用金乌骨通胶囊单用或联合常规西药治疗。
- 联合NSAIDs、透明质酸或氨基葡萄糖可能增强疗效并减少不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The Jinwu Gutong (JWGT) capsule is a Chinese patent medicine that is widely used in the treatment of knee osteoarthritis (KOA) and osteoporosis in China and is considered to have the potential for good clinical efficacy. AIM OF THE STUDY: The purpose of this study was to systematically evaluate the clinical efficacy and safety of JWGT in the treatment of KOA. MATERIALS AND METHODS: We searched the China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, PubMed, Embase and Cochrane Library databases to identify clinical trials that explore the use of JWGT only or JWGT combined with Western drugs (JWGT group) compared with the use of conventional Western drugs (Western drugs group) for the treatment of KOA. The clinical trials, that were retrieved from each database from the inception of the database to December 2021, were screened. We used the risk of bias assessment tool recommended by Cochrane to evaluate the quality of the included literature and RevMan 5.3 software for data analysis. RESULTS: A total of 17 clinical randomized controlled trials (RCTs) were included in this study, with a total of 1930 participants, including 1015 people in the experimental group and 915 people in the control group. The results of the meta-analysis showed that the JWGT group exhibited better efficacy than the Western drug group with respect to WOMAC score (WMD = -6.25, 95% CI = -8.09 to -4.41, P < 0.001), VAS score (WMD = -1.36, 95% CI = -2.17 to -0.55, P = 0.001), KSS score (WMD = 23.01, 95% CI = 21.42 to 24.59, P < 0.001), IL-6 (SMD = -3.30, 95% CI = -4.84 to -1.76, P < 0.001), TNF-α (SMD = -1.70, 95% CI = -2.02 to -1.38, P < 0.001). The effective rate (OR = 2.56, 95% CI = 1.83 to 3.57, P < 0.001) and incidence of adverse reactions was significantly lower in the JWGT group than in the control group (OR = 0.13, 95% CI = 0.07 to 0.21, P < 0.001). Subgroup analysis showed that JWGT + NSAIDs had more advantages in regard to efficacy (OR = 2.05, 95% CI = 1.35 to 3.12, P < 0.001), and reducing adverse reactions (OR = 0.10, 95% CI = 0.06 to 0.18, P < 0.001), VAS score (WMD = -1.00, 95% CI = -1.93 to -0.07, P = 0.04), KSS score (WMD = 17.39, 95% CI = 15.39 to 19.39, P < 0.001), WOMAC score (WMD = -2.84, 95% CI = -10.75 to 5.08, P < 0.001), IL-6 (SMD = -1.42, 95% CI = -2.08 to -0.75, P < 0.001) and TNF-α (SMD = -1.68, 95% CI = -1.93 to -1.43, P < 0.001) than NSAIDs alone. Compared with hyaluronic acid (HA) alone, JWGT + HA had better clinical efficacy (OR = 3.08, 95% CI = 1.48 to 6.40, P < 0.001). Compared with glucosamine (GS) alone, JWGT + GS significantly reduced the Lequesne index score (WMD = -0.53, 95% CI = -0.85 to -0.21, P = 0.001) and the serum TNF-α level (SMD = -1.68, 95% CI = -1.93 to -1.43, P < 0.001), but it had no significant advantage in reducing the serum IL-6 level (SMD = -4.53, 95% CI = -10.13 to 1.07, P = 0.11). CONCLUSION: JWGT is considered effective and safe in the treatment of KOA and is worthy of clinical application. In addition, the application of JWGT combined with NSAIDs, HA or GS can significantly improve the clinical efficacy of the latter agents in KOA treatment.
引用
- Zhao J, Yang W, Liang G, et al. The efficacy and safety of Jinwu Gutong capsule in the treatment of knee osteoarthritis: A meta-analysis of randomized controlled trials. J Ethnopharmacol. 2022. PMID: 35390472. doi:10.1016/j.jep.2022.115247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。